1. Home
  2. VIR vs UVE Comparison

VIR vs UVE Comparison

Compare VIR & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • UVE
  • Stock Information
  • Founded
  • VIR 2016
  • UVE 1990
  • Country
  • VIR United States
  • UVE United States
  • Employees
  • VIR N/A
  • UVE N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • UVE Property-Casualty Insurers
  • Sector
  • VIR Health Care
  • UVE Finance
  • Exchange
  • VIR Nasdaq
  • UVE Nasdaq
  • Market Cap
  • VIR 706.4M
  • UVE 666.1M
  • IPO Year
  • VIR 2019
  • UVE 1992
  • Fundamental
  • Price
  • VIR $5.08
  • UVE $25.52
  • Analyst Decision
  • VIR Strong Buy
  • UVE
  • Analyst Count
  • VIR 10
  • UVE 0
  • Target Price
  • VIR $26.80
  • UVE N/A
  • AVG Volume (30 Days)
  • VIR 1.5M
  • UVE 139.0K
  • Earning Date
  • VIR 10-30-2025
  • UVE 10-23-2025
  • Dividend Yield
  • VIR N/A
  • UVE 3.10%
  • EPS Growth
  • VIR N/A
  • UVE N/A
  • EPS
  • VIR N/A
  • UVE 2.28
  • Revenue
  • VIR $19,000,000.00
  • UVE $1,567,371,000.00
  • Revenue This Year
  • VIR N/A
  • UVE $1.87
  • Revenue Next Year
  • VIR $9.65
  • UVE N/A
  • P/E Ratio
  • VIR N/A
  • UVE $10.89
  • Revenue Growth
  • VIR N/A
  • UVE 5.64
  • 52 Week Low
  • VIR $4.16
  • UVE $16.50
  • 52 Week High
  • VIR $14.45
  • UVE $28.49
  • Technical
  • Relative Strength Index (RSI)
  • VIR 51.83
  • UVE 59.54
  • Support Level
  • VIR $5.04
  • UVE $24.13
  • Resistance Level
  • VIR $5.39
  • UVE $25.67
  • Average True Range (ATR)
  • VIR 0.34
  • UVE 0.59
  • MACD
  • VIR 0.05
  • UVE 0.12
  • Stochastic Oscillator
  • VIR 49.20
  • UVE 78.95

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

Share on Social Networks: